Analyses of biopsies before and after treatment with BsAbs targeting EGFR (amivantamab) or HER2 (zintokalimab) have demonstrated substantial intercellular variation in antigen density within single tumor niches (210–212). This evidence concerns the gene ERBB2 and neoplasm.